galumay
learner
- Joined
- 17 September 2011
- Posts
- 3,441
- Reactions
- 2,279
My pick for the comp. Am hoping for a bit of a bounce next month after the long suspension from trading, after those who want to sell get out. Great science but very poor overpaid management. 4c has shown a bit of improvement on the cost front, but biggest hope for this is a takeover.
Indeed.Looks like the selling has finished and buyers are in charge. Just need a bit of good news now to really get it going.
A few more months of today's action and I'll start feeling cheerful.
Looking at the results, the auditor and board comments, this outfit has 18 mo. max left before it is totally out of cash without a significant injection or raise of capital.With a restructuring of the company, I admit it's beyond my forensics to decipher the financial statements, half yearly report ending June 2020 may be enlightening to some ...
https://www.asx.com.au/asxpdf/20200820/pdf/44lq90nlmp0lrc.pdf
... although I gather Anteris has a couple more quarters in it, without the necessity of yet another cap-raise.
P
For this "structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients, [with its] focus .. on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings", would a mill help?Looking at the results, the auditor and board comments, this outfit has 18 mo. max left before it is totally out of cash without a significant injection or raise of capital.
For this "structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients, [with its] focus .. on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings", would a mill help?
Highlights
• $1.1M raised in a placement to sophisticated investors at $3.37 per share – 10% discount to the last closing share price
• Provides working capital as Anteris continues to demonstrate superior performance of the DurAVR™, 3D single-piece, aortic valve
View attachment 117410
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?